scholarly journals Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban

2021 ◽  
Vol Volume 13 ◽  
pp. 181-184
Author(s):  
Takla R Anis ◽  
Whitney Jandreau
Keyword(s):  
Case Report ◽  
Cross Reactivity ◽  
Pruritic Rash

A case report of oral lichenoid lesions related to cross‐reactivity between nickel and palladium

2021 ◽  
Author(s):  
Fumihiko Tsushima ◽  
Jinkyo Sakurai ◽  
Risa Shimizu ◽  
Hiroyuki Harada
Keyword(s):  
Case Report ◽  
Cross Reactivity ◽  
Oral Lichenoid Lesions

scholarly journals Photodistributed sarcoidosis: a case report and approach to management

2018 ◽  
Vol 6 ◽  
pp. 2050313X1879687
Author(s):  
Cristina Olteanu ◽  
Brandon Worley ◽  
Iris Teo ◽  
Jillian Macdonald
Keyword(s):  
Case Report ◽  
Ionizing Radiation ◽  
Bone Pain ◽  
Prior Exposure ◽  
Systemic Involvement ◽  
Pruritic Rash ◽  
Cutaneous Involvement ◽  
Multiple Organs ◽  
History Of ◽  
Idiopathic Disease

Sarcoidosis is an idiopathic disease, characterized by non-caseating granulomas in multiple organs/tissues. Cutaneous involvement occurs in approximately one-quarter of patients with a wide variety of presenting morphologies. This case report describes a case of photodistributed sarcoidosis, a rare cutaneous variant, with systemic involvement. A 42-year-old man presented with a history of a pruritic, rash with photoexacerbated annular plaques along with arthralgias and bone pain. Compared to previous reports of photodistributed sarcoidosis, our case presented with annular plaques rather than papules, and there was no prior exposure to ionizing radiation. He was treated successfully with prednisone and hydroxychloroquine. It is important to include sarcoidosis in the differential of photodistributed dermatoses.

scholarly journals Fixed drug eruption (FDE) induced by mefenamic acid with unusually cross‐reactivity to diclofenac: A case report

2020 ◽  
Author(s):  
Bouraoui Ouni ◽  
Neila Fathallah ◽  
Nesrine Ben‐Sayed ◽  
Nihed Abdessayed ◽  
Raoudha Slim ◽  
...  
Keyword(s):  
Case Report ◽  
Mefenamic Acid ◽  
Drug Eruption ◽  
Cross Reactivity ◽  
Fixed Drug Eruption ◽  
Fixed Drug

Cross-Reactivity between Aspirin and Ibuprofen in an Asthmatic—A Case Report

1978 ◽  
Vol 35 (10) ◽  
pp. 1245-1250
Author(s):  
Gerald J. Merritt ◽  
Robert I. Selle
Keyword(s):  
Case Report ◽  
Cross Reactivity

Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report

2001 ◽  
Vol 29 (4) ◽  
pp. 133-136 ◽  
Author(s):  
M.J. Trujillo ◽  
M. de Barrio ◽  
A. Rodríguez ◽  
M. Moreno-Zazo ◽  
I. Sánchez ◽  
...  
Keyword(s):  
Case Report ◽  
Cross Reactivity

Potential cross-reactivity of polysorbate 80 and cremophor: A case report

2020 ◽  
Vol 26 (5) ◽  
pp. 1279-1281 ◽  
Author(s):  
Mark Allen T Bibera ◽  
Kristina M K Lo ◽  
Aaron Steele
Keyword(s):  
Case Report ◽  
Test Dose ◽  
Cross Reactivity ◽  
Drug Formulation ◽  
Polysorbate 80 ◽  
Hypersensitivity Reactions ◽  
Drug Products ◽  
Unique Event ◽  
Patient Reported ◽  
Difficulty Breathing

Introduction Anaphylactic and hypersensitivity reactions are known adverse effects of many drug products and may be due to the inactive ingredients of the drug formulation. Specifically for paclitaxel and docetaxel, it is their excipients (cremophor and polysorbate 80, respectively) that have been identified as being most likely responsible for these reactions. Case report The patient is a 39-year-old female, with a history of breast cancer and no known allergies, who was scheduled to start chemotherapy. While being administered fosaprepitant, she reported shortness of breath and was noted to be hypotensive and flushed. Two months later, the patient returned to clinic to start weekly paclitaxel. During the administration of the paclitxel test dose, the patient reported difficulty breathing, flushing, and chest tightness. Management and outcome: Both medication reactions were managed with epinephrine and other supportive medications. Fosaprepitant was taken out of the patient’s antiemetic regimen for future cycles and paclitaxel was switched to nab-paclitaxel. Discussion It is well documented that paclitaxel and fosaprepitant have the potential to cause hypersensitivity reactions due to their excipients. While it is likely that each reaction was a unique event, it is difficult to ignore the possibility of cross-reactivity due to the presence of oleic acid in both excipients.

Sign in / Sign up

Export Citation Format

Share Document